Table 3.
Myeloid neoplasm features.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Time from CART to MDS diagnosis (months) | 9 | 6 | 5 | 13 | NA |
| Progression to AML | No | Yes | No | No | No |
| R-IPSS | Very High (7) |
Very high (7) |
Intermediate (3.5) |
Very low (1.5) |
Very High (6.5) |
| IPSS-M * | Very high (2.54) |
Very high (2.75) |
High (1.39) |
Very low (−1.17) |
Very high (1.86) |
| Cytopenias: WBC Hemoglobin MCV Platelets |
2.5 8 79 43,000 |
2.5 9.1 108 33,000 |
2.9 8.9 105 53,000 |
3.7 12.8 100 76,000 |
2 8.8 110 14,000 |
| Blasts (%) | 5 | 15 | 0.7 | 0 | 2 |
| Cytogenetic abnormalities | 44, XY, −3, der (5), −7 [1]/46, XY, −3, der (5), +mar1 [1]/43, idem, −21 [3]/44–45, idem, +mar1, +mar2, +mar3 [5] | 46, XY, +1, der (1;7) (q10;p10) [10] | 46, XY, −5, +mar [7]/46, XY, del (5) (q13q34) [2]/46, XY [11] | 46, XY [20] | 45, XY, −7 [4/30] |
| Mutated genes | TP53 | RUNX1, DNMT3A, PHF6, PPM1D, RUNX1 | TP53 (2 different mutations) | RAD21, TET2 | RUNX1, DNMT3A, TET2 |
| Survival since MDS diagnosis (months) | 1 | 2 | 12 | 4 Ongoing |
7 |
| Survival (months) from CART/Cause of death | 10 COVID-19 infection |
8 MM |
17 Infection |
17 Alive |
7 MM |
IPSS-R—revised international prognostic scoring system; IPSS-M—molecular international prognostic scoring system * https://mds-risk-model.com/ (accessed on 1 February 2023).